Date of publication: January 16,
2006
Source:
http://gmoinfo.jrc.it/gmp_browse_geninf.asp
Notification number:
B/FR/06/01/02
Member State: France
Date of Acknowledgement: 12/12/2005
Title of the Project:
Five year field trials programme (2006-2010) for the
deliberate release of MON 88017 maize protected against certain
coleopteran insect pests (Diabrotica spp) and tolerant to
glyphosate
Proposed period of release From:01/04/2006
To:31/12/2010
Name of the Institute(s) or Company(ies): Monsanto
Company represented by Monsanto Agriculture France S.A.S;
3. Is the same GMPt release planned elsewhere in the
Community?
Yes: Germany; Spain
4 - Has the same GMPt been notified elsewhere by the same
notifier?
No
Genetically
modified plant
1. Complete name of the
recipient or parental plant(s)
|
Common Name
|
Family Name
|
Genus |
Species
|
Subspecies
|
Cultivar/breeding line
|
| maize
|
poaceae |
zea
|
zea
mays |
mays
|
|
2. Description of the traits and characteristics which have
been introduced or modified, including marker genes and previous
modifications:
MON 88017 that will be tested in these field trials is
protected to certain coleopteran insect pests (Diabrotica spp)
and is tolerant to glyphosate herbicide.
Genetic
modification
3. Type of genetic
modification:
Insertion;
4. In case of insertion of genetic material, give the source
and intended function of each constituent fragment of the region
to be inserted:
MON 88017 contains the following genetic elements :
- the cry3Bb1 gene from Bacillus thuringiensis subsp.
kumamotoensis which confers protection against certain
coleopteran pests (Diabrotica spp)
- the cp4 epsps gene from Agrobacterium sp. strain CP4, which
provides tolerance to ghyphosate herbicide.
These genes have been introduced with regulatory elements
necessary for expressioin in plant cells.
6. Brief description of the method used for the genetic
modification:
MON 88017 was produced by Agrobacterium-mediated
transformation of immature embryos of maize tissue.
7. If the recipient or parental plant is a forest tree
species, describe ways and extent of dissemination and specific
factors affecting dissemination:
Not applicable
Experimental
Release
1. Purpose of the release:
The aims of the release are:
1. to characterize MON 88017 maize under European crop
conditions, including analysis for protein expression.
2. to evaluate the agronomic performance and equivalence of MON
88017 to conventional maize.
3. to evaluate residues after applications with herbicide
formulations based on glyphosate.
2. Geographical location of the site:
The releases are planned at several locations in 2006
(Midi-Pyrénées, Aquitaine, Poitou-Charentes, Centre).
3. Size of the site (m2):
Each site will have a maximum of 5 000 m² sown with MON 88017
concerned by this application, the total area covered by the
trial will be higher.
4. Relevant data regarding previous releases carried out with
the same GM-plant, if any, specifically related to the potential
environmental and human health impacts from the release:
Many field trials have already been conducted at several
locations across maize growing regions in North and South
America. No environmental problems were reported for these
trials. Except for its protection against certain coleopteran
insects and its tolerance to glyphosate herbicide, MON 88017
could not be distinguished from conventional maize.
Insect-protection and glyphosate tolerance traits present in MON
88017 are present, alone or in combination, in commercial
products, NK603, MON 863 and MON 863 x NK603, which have a
safety commercial experience.
Environmental
Impact and Risk Management
Summary of the potential
environmental impact from the release of the GMPts:
Analysis of the characteristics of MON 88017 maize,
especially in comparison with extensive experience with
cultivation of conventional maize within the E.U., has shown
that the risk for potential adverse effects on human and animal
health and the receiving environment, resulting from the planned
field trials with MON 88017 maize, is negligible:
- The risk of the introduced traits in MON 88017 maize to be the
cause of any meaningful competitive advantage or disadvantage in
natural environments is negligible. As for any other maize, the
likelihood of this maize to spread into non-agronomic
environments is negligible, as its persistence in agricultural
habitats and its invasiveness into natural habitats are
unaltered compared to conventional maize.
- Potential exposure of non-target organisms to CP4 EPSPS
presents no conceivable mechanism to cause adverse effects
because of its properties. Due to the high selectivity of
Cry3Bb1 protein to certain coleopteran insects and based on
studies with different species, the risk for non target
organisms is considered negligible. The ecological interactions
of MON 88017 maize with non target organisms or soil process are
considered similar to the respective caused by conventional corn
- Any occupational health aspects of handling MON 88017 maize
are not different from conventional maize, and this maize was
shown to be as safe and as nutritious as any other maize.
- The environmental impact of the cultivation, management and
harvesting techniques applied in the planned trials is
considered no different from the farming practices for
conventional maize.
It is actually expected that the commercial production of MON
88017 maize will positively impact current agronomic practices
in maize and provide benefits to farmers and the environment.
The protection against D. virgifera would offer a new tool for
IPM and would reduce the reliance on chemical pesticides whereas
the use of glyphosate in maize would enable the farmer to take
advantage of the herbicide’s favorable environmental and safety
properties (see Annex I listing of glyphosate under Council
Directive 91/414/EEC) as well as facilitate adoption of
conservation tillage practice in corn production
Maize can hybridize with teosinte but these plants are not
present in Europe. Measures will be taken to avoid hybridization
with other maize plants and seed dissemination at harvest and
during transportation (see E.)
Brief description of any measures taken for the management of
risks:
1. In addition to the scheduled observations of phenotypic
and agronomic parameters that form the basis of the planned
research, the trial site will be checked regularly during the
period of the deliberate release for potentially occurring,
direct or indirect, adverse environmental effects. This will be
done by visual inspection of the status of the MON88017 crop and
that of its receiving environment. In case any adverse
environmental effects, linked to the deliberate release of MON
88017, are observed during the period of release, these will be
reported immediately to the Competent Authority.
2. The spatial isolation distance (200 m) from other maize crops
and the four rows of conventional maize surrounding the trials
will prevent most of the possibility of hybridisation with other
maize plants. Some trials (efficacy especially) could be carried
out without isolation. In this case, the trials will be
destroyed before the flowering stage of the crop.
3. The equipment, especially the experimental drill and combine,
will be cleaned on the experimental site, thus preventing seed
dissemination.
4. After completion of harvest, the stalks will be chopped and
then incorporated into the soil. Any shattered seed will be
allowed to germinate. The resulting seedlings will be destroyed
by soil incorporation. Maize cobs will be harvested by
experimental-plot combine, or by hand.
5. Although regrouwth in the rotation crops is unlikely because
of poor winter survival, the site will be sown either with a
crop different from maize or with experimental maize that will
be destroyed and not used in any commercial, industrial or food
application. Volunteer plants will be controlled by the use of
routinely used commercial antimonocotyledonous herbicides in
this crop.
6. Seeds will be transported in sealed and labelled bags placed
in a rigid container.
Summary of foreseen field trial studies focused to gain new
data on environmental and human health impact from the release:
Not applicable.
However, any unanticipated adverse effects on human health or
the environment would be reported immediately to the Competent
Authority.
Final report
-
European Commission administrative
information
Consent given by the Competent Authority: Not Known |
